Tate & Lyle PLC
Tate & Lyle PLC
RESOLUTION OF A.E. STALEY LITIGATION
Tate & Lyle PLC announced today that its subsidiary A.E. Staley Manufacturing
Company ('Staley') has reached agreement to end the long running high fructose
corn syrup ('HFCS') civil antitrust legal case.
Under the terms of the settlement, Staley will pay total damages of $100 million
(£55 million). This will result in an exceptional charge to the profit and loss
account of this amount. As the payment is expected to be tax deductible in the
US, this equates to a charge of $60 million (£33 million) on an after tax basis.
The settlement funds will be paid into escrow by Staley during the next week.
The settlement needs to be formally approved by the United States District Court
for the Central District of Illinois.
Staley continues to deny emphatically involvement in any wrongdoing, but has
settled with great reluctance to ensure an end to this lengthy action and to
avoid the risk and uncertainty that a US jury trial would involve.
Staley was one of a number of manufacturers of HFCS, including Archer Daniels
Midland (ADM) and Cargill, targeted by plaintiffs' lawyers in a class action
that alleged violations of certain anti-trust laws during the period 1988 to
1995. The action was brought on behalf of purchasers of HFCS during that period,
primarily US food and beverage manufacturers. Damages claimed in the case
amounted to $1.4 billion, subject to automatic tripling and the addition of
attorneys' fees. Under US civil anti-trust laws, defendants in trials of this
type are jointly and severally liable for any damages awarded to the plaintiff.
The case was filed with the United States District Court for the Central
District of Illinois in Peoria in July 1995, but dismissed by that Court in
August 2001. That dismissal was overturned by the United States Court of Appeals
for the Seventh Circuit in June 2002. The case was proceeding to a full jury
trial in early September 2004. On 15th March 2004, the District Court approved
Cargill's (and American Maize Product Company's) settlement with the Plaintiffs
in the amount of $24 million. On 17th June 2004, ADM announced that it had
agreed to settle for $400 million. The settlement announced today brings the
action to a complete end.
Robert Gibber, Tate & Lyle PLC General Counsel, commented:
'In 1995, a Grand Jury reviewed millions of pages of evidence yet brought no
charges against any manufacturer of HFCS. However, as is typical in the US, this
was followed by a civil class action alleging violations of federal anti-trust
laws.
'We deny emphatically involvement in any wrongdoing and believe we were in a
position to demonstrate this at trial. However, particularly in light of the
recent settlements by the other defendants, a jury trial would have exposed
Staley to a degree of risk, itself magnified by automatic tripling of damages
and the addition of attorneys' fees, which could not be justified. For this
reason we reluctantly decided to settle on the best terms available from the
plaintiffs as announced today. This agreement does not involve any admission of
liability but does remove the uncertainties hanging over Staley from these
proceedings.'
CONTACTS
Mark Robinson, Head of Investor Relations
Tel: 020 7626 6525 or Mobile: 07793 515861 investorrelations@tateandlyle.com
Chris Fox, Director of Corporate Relations (Press)
Tel: 020 7626 6525 or Mobile: 07801 808553
Tate & Lyle is a world leader in ingredients. Its core competence is to take
corn, wheat or sugar, and add value to these raw materials through technology.
As a result of continuous innovation it offers an ever-wider product portfolio
of versatile and functional ingredients. These products include Cereal
Sweeteners, Starches, Sugars, Citric Acid and SPLENDA(R)Sucralose. Tate & Lyle
products have wide applications in the food, beverage, pharmaceutical, cosmetic,
paper, packaging and building industries. With headquarters in London, Tate &
Lyle operates more than 41 plants and 20 additional production facilities in 28
countries, almost all in Europe and the Americas. It employs 6,700 people in its
subsidiaries with a further 4,800 employed in joint ventures. Sales in the year
to 31 March 2004 totalled £3,167 million. More details are available on this
website www.tateandlyle.com.
SPLENDA(R) is a trademark of McNeil-PPC, Inc.
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.